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were generated and digitized. The H&E sections were registered to 
the MRI with a registration-error less than 3 mm. Spearman’s 
correlation between tumor ADC and micro anatomical variables were 
calculated using an automatic pixel counting algorithm 
(AperioTechnologies) (Figure 1). 
 
  
Results: ADC was significantly and inversely correlated to cell density, 
percentage area of nuclei and N/C ratio. ADC was significantly and 
positively related to percentage area of stroma. Additionally, the 
percentage area of stroma was strongly interdependent with the 
percentage area of nuclei (Table 1). 
 
  
Conclusions: ADC was significantly correlated with cellularity, stromal 
component and the nuclear-to-cytoplasm ratio. These results give us 
insights into how ADC reflects the underlying microanatomical 
environment. The correlation between stromal component, a known 
predictor of local failure, and ADC might suggest that the poor 
prognostic value of a high pre-treatment ADC might partly be 
attributed to the tumor-stroma component. 
[1]Hakatenaka et al, Int J Radiat Oncol Biol Phys. 2011 
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Purpose/Objective: Dynamic contrast enhanced CT imaging 
('perfusion CT') is a technique for the quantification of vasculature 
inside tumours. If combined with FDG-PET/CT imaging a more 
complete assessment of the tumour heterogeneity is possible. In this 
study we investigated non-small cell lung cancer (NSCLC) patients 
undergoing both techniques on the same day to quantify the 
correlation of vasculature properties with metabolically active 
regions. 
Materials and Methods: A total of 12 patients diagnosed with stage II-
III NSCLC were analysed from two ongoing clinical trials (NCT01024829 
and NCT01210378) prior to (chemo-)radiotherapy treatment were 
scheduled for FDG-PET/CT (Siemens Biograph 40 PET/CT) and 
perfusion CT (Siemens Definition Flash CT) imaging. The primary gross 
tumour volume (GTV) was delineated on the PET/CT scan for 
treatment planning purposes. Datasets of both imaging modalities 
(FDG-PET/CT and perfusion CT) were registered and metabolic uptake 
regions on the FDG-PET/CT were thresholded in 2 regions inside the 
GTV: a low (0-50% of the maximum SUV) and high metabolic uptake 
(>50% of the maximum SUV). Commercial perfusion CT software 
(Siemens VPCT; deconvolution algorithm approach) was used to 
extract inside the 2 thresholded regions the vasculature properties op 
the tumour: blood flow (BF), blood volume (BV), permeability (PMB) 
and mean transit time (MTT). Differences in vasculature between low 
and high uptake volumes were assessed. 
Results: Differences (mean±1SD) were observed between low and high 
metabolically active regions: average BF (ml/100ml/min) 52±33 vs. 
68±39 ml/100ml/min (p=0.03), average BV (ml/100ml) was 6.6±4.4 vs. 
9.3±6.0 (p=0.06), MTT 5.8±3.8 vs. 6.0±4.1 s (p=0.62) and PMB 
(ml/100ml/min) was 13±19 vs. 20±27 (p<0.01), respectively. 
Conclusions: Regions that are metabolically active on the FDG-PET 
scan also show increased blood flow, volume and permeability 
indicating more vascularised tumour parts. Mean transit times for the 
contrast were not different. These findings yield the potential to use 
perfusion imaging for characterization of vasculature in staging and 
follow-up of NSCLC patients scheduled for multi-modality therapy.  
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Purpose/Objective: Tumour hypoxia is an important marker of cancer 
prognosis, being associated with aggressive growth, metastasis and 
resistance to anticancer therapy. Imaging of tumour hypoxia could 
help to select patients for anti-hypoxia therapy and/or for a radiation 
boost to the hypoxic tumour regions. Pre-clinical data and phase I 
human trials have shown that [18F]HX4 is a novel promising Positron 
Emission Tomography (PET) tracer for the evaluation of tumour 
hypoxia. The aims of the study were to evaluate the [18F]HX4 uptake, 
the optimal imaging time-point after injection and the spatiotemporal 
stability in NSCLC patients. 
Materials and Methods: 13 NSCLC patients (stage IIB-IV) included in 2 
clinical trials (NCT01024829 and NCT01210378) were imaged on a 
PET/CT scanner using the hypoxia tracer: [18F]HX4. 413±71 MBq of 
[18F]HX4 was injected intravenously and at 2 and 4 hours p.i. PET 
acquisitions (30 min static) were acquired. SUV-max and SUVmean were 
extracted from the gross tumour volumes (GTVs) and aortic arch to 
calculate tumour-to-blood ratios (TBR). The Wilcoxon signed rank test 
was used to determine significant differences in uptake between 2h 
and 4h post injection (p.i.) The tumour hypoxic fraction (HF), defined 
as the fraction of the GTV with a TBR>1.4, was determined for all 
lesions (i.e. primary tumour and lymph nodes). To evaluate the 
spatiotemporal stability, images acquired at 2h and 4h p.i. were 
rigidly registered and a voxelwise comparison of the [18F]HX4 uptake 
was made, expressed as a Pearson correlation coefficient. 
Results: Analysis of the first 13 NSCLC patients (9 male, 4 female, 
age: 62±12 y), indicated significant uptake (TBR>1.4) in 18/25 target 
lesions (13 primary tumours and 12 lymph nodes) with an average HF 
of 20±21% (range: 0.2-71%) at 4h p.i.. 85% (11/13) of the primary 
tumours and 58% (7/12) of the involved lymph nodes were hypoxic. 
There was no correlation between the GTV and HF (R=0.25, P=0.24). 
Within the 18 hypoxic lesions, the average tumour SUVmax decreased 
significantly (P=0.004) from 2h (1.4±0.4) to 4h p.i. (1.2±0.4). 
However, due to clearance of [18F]HX4 in the blood, the TBR increased 
significantly (P<0.001) between 2h and 4h p.i. from 1.6±0.3 to 2.0±0.5 
(see figure). The heterogeneous [18F]HX4 uptake pattern at 2h and 4h 
p.i. showed a strong correlation (R=0.76±0.09, range: 0.58-0.94). 
 
  
Conclusions: Significant hypoxia was observed in 72% of the NSCLC 
target lesions (85% of primary tumours and 58% of the involved lymph 
nodes). The heterogeneous [18F]HX4 uptake pattern was stable 
between 2h and 4h p.i., however the TBR increased over time, 
